Acute Antibody-mediated Rejection 1 Week After Lung Transplantation Successfully Treated With Eculizumab, Intravenous Immunoglobulins, and Rituximab
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:102 |
|---|---|
| Enthalten in: |
Transplantation - 102(2018), 6 vom: 15. Juni, Seite e301-e303 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Muller, Yannick D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 28.01.2019 Date Revised 28.01.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/TP.0000000000002165 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM281784655 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM281784655 | ||
| 003 | DE-627 | ||
| 005 | 20231225032431.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/TP.0000000000002165 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0939.xml |
| 035 | |a (DE-627)NLM281784655 | ||
| 035 | |a (NLM)29521880 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Muller, Yannick D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Acute Antibody-mediated Rejection 1 Week After Lung Transplantation Successfully Treated With Eculizumab, Intravenous Immunoglobulins, and Rituximab |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.01.2019 | ||
| 500 | |a Date Revised 28.01.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Isoantibodies |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a eculizumab |2 NLM | |
| 650 | 7 | |a A3ULP0F556 |2 NLM | |
| 700 | 1 | |a Aubert, John-David |e verfasserin |4 aut | |
| 700 | 1 | |a Vionnet, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Rotman, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Sadallah, Salima |e verfasserin |4 aut | |
| 700 | 1 | |a Aubert, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Pascual, Manuel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplantation |d 1963 |g 102(2018), 6 vom: 15. Juni, Seite e301-e303 |w (DE-627)NLM000023787 |x 1534-6080 |7 nnns |
| 773 | 1 | 8 | |g volume:102 |g year:2018 |g number:6 |g day:15 |g month:06 |g pages:e301-e303 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/TP.0000000000002165 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 102 |j 2018 |e 6 |b 15 |c 06 |h e301-e303 | ||